Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cilomilast (SB-207499) 是选择性的、口服具有活性的磷酸二酯酶 4 抑制剂。 它对 PDE4 的选择性高于 PDE1,PDE2,PDE3 和 PDE5 (IC50=74,65,<100,83 µM)。它具有抗炎和免疫调节功能,可用于研究哮喘和慢性阻塞性肺疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 297 | 现货 | ||
2 mg | ¥ 435 | 现货 | ||
5 mg | ¥ 619 | 现货 | ||
10 mg | ¥ 993 | 现货 | ||
25 mg | ¥ 1,920 | 现货 | ||
50 mg | ¥ 3,180 | 现货 | ||
100 mg | ¥ 4,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 683 | 现货 |
产品描述 | Cilomilast (SB-207499) is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. Phase 3. |
靶点活性 | LPDE4:100 nM |
体外活性 | Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. [2] In isolated human monocytes, Cilomilast and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both Cilomilast and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. Cilomilast and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively. [2] Cilomilast significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Cilomilast treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes. [3] Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity. [4] |
体内活性 | Cilomilast inhibits human TNFα production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFα production, Cilomilast (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity. [1] In time course studies, Cilomilast (30 mg/kg, p.o.) suppresses TNFα production for at least 10 hour. The ability of Cilomilast to modulate interleukin-4 productionin vivo is assessed in a chronic oxazolone-induced contact sensitivity model in Balb/c mice. Topical administration of Cilomilast (1000 μg) inhibits intralesional concentrations of interleukin-4. [1] Orally administered cilomilast dose-dependently inhibits production of interleukin-4, TNF-α, and cysteinyl leukotrienes, as well as leukocyte infiltration in bronchoalveolar lavage fluid from the airways of ovalbumin-sensitized Brown Norway rats [5]. |
细胞实验 | U937 cells (1-2 × 10 6) are incubated at 37 °C in a shaking water bath with Cilomilast for 1 min before the addition of 0.1 μM PGE2 (total volume of 200 μL). The incubation proceeds for an additional 4 min and is stopped by the addition of 0.1 mL of HClO4 (17.5%), neutralized with 0.15 ml of K2</subCO3 (1.0 M) and diluted to 1 mL with sodium acetate buffer. Samples are centrifuged at 3000 × g for 10 min. Aliquots of the supernatant fraction are assayed for cAMP content by radioimmunoassay using commercially available kits.(Only for Reference) |
别名 | SB-207499, 西洛司特, Ariflo |
分子量 | 343.42 |
分子式 | C20H25NO4 |
CAS No. | 153259-65-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 31 mg/mL(90.3 mM)
DMSO: 64 mg/mL (186.4 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.9119 mL | 14.5594 mL | 29.1189 mL | 72.7972 mL |
5 mM | 0.5824 mL | 2.9119 mL | 5.8238 mL | 14.5594 mL | |
10 mM | 0.2912 mL | 1.4559 mL | 2.9119 mL | 7.2797 mL | |
20 mM | 0.1456 mL | 0.728 mL | 1.4559 mL | 3.6399 mL | |
50 mM | 0.0582 mL | 0.2912 mL | 0.5824 mL | 1.4559 mL | |
DMSO | 100 mM | 0.0291 mL | 0.1456 mL | 0.2912 mL | 0.728 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Cilomilast 153259-65-5 Metabolism PDE asthma immunomodulatory obstructive Inhibitor Phosphodiesterase (PDE) inhibit SB207499 Phosphodiesterase SB 207499 SB-207499 西洛司特 pulmonary disease PDE4 anti-inflammatory chronic COPD Ariflo inhibitor